D. E. Shaw & Co. Inc. decreased its holdings in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 23.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 488,306 shares of the medical equipment provider's stock after selling 146,038 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 1.11% of AxoGen worth $8,047,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. R Squared Ltd bought a new position in shares of AxoGen in the 4th quarter worth about $30,000. US Bancorp DE bought a new stake in AxoGen in the fourth quarter worth approximately $30,000. Harvest Fund Management Co. Ltd acquired a new position in AxoGen in the fourth quarter valued at approximately $93,000. Fox Run Management L.L.C. bought a new position in shares of AxoGen during the 4th quarter worth approximately $169,000. Finally, Sei Investments Co. bought a new stake in shares of AxoGen in the 4th quarter valued at $188,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.
AxoGen Stock Performance
Shares of AxoGen stock traded up $0.20 during mid-day trading on Wednesday, hitting $11.77. 71,201 shares of the stock were exchanged, compared to its average volume of 461,980. The company has a 50-day simple moving average of $15.91 and a 200 day simple moving average of $16.20. The company has a market capitalization of $536.19 million, a P/E ratio of -36.67 and a beta of 1.19. AxoGen, Inc. has a 12 month low of $5.90 and a 12 month high of $21.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $24.00 price objective on shares of AxoGen in a report on Wednesday, March 5th. Canaccord Genuity Group cut their target price on AxoGen from $26.00 to $24.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Lake Street Capital assumed coverage on shares of AxoGen in a report on Monday, March 17th. They set a "buy" rating and a $30.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $22.20.
Check Out Our Latest Stock Analysis on AXGN
Insider Buying and Selling
In other news, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the transaction, the director now directly owns 97,899 shares of the company's stock, valued at $1,959,937.98. This represents a 4.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares in the company, valued at $3,810,835. This represents a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.78% of the stock is owned by insiders.
About AxoGen
(
Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Further Reading
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
